Fluorine-18 P17 059
Alternative Names: [18F]D6-FP-DTBZ; [18F]D6FP; [18F]P17-059; Deuterated [18F]hexadeuterofluoropropyl-(+)-dihydrotetrabenazineLatest Information Update: 18 Jan 2023
At a glance
- Originator Five Eleven Pharma
- Class Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Parkinson's disease
Most Recent Events
- 19 Dec 2022 Five Eleven Pharma completes phase I clinical trial in Parkinson's disease (Diagnosis) in USA (IV) (NCT03903549)
- 05 May 2022 Phase-I clinical trials in Parkinson's disease (Diagnosis) in USA (IV) (NCT03903549)
- 04 Apr 2019 Five Eleven Pharma plans a phase I trial for Parkinson's disease (Diagnosis) in USA in April 2020 (IV) (NCT03903549)